Asthika Goonewardene
Stock Analyst at Leerink Partners
(2.82)
# 2,820
Out of 5,124 analysts
322
Total ratings
40.5%
Success rate
1.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMAB Genmab | Reiterated: Buy | $48 → $65 | $55.80 | +16.49% | 41 | Oct 29, 2026 | |
| AVBP ArriVent BioPharma | Reiterated: Buy | $32 → $45 | $14.16 | +217.80% | 6 | Aug 13, 2026 | |
| ACET Adicet Bio | Reiterated: Buy | n/a | $2.99 | - | 14 | Mar 16, 2026 | |
| ALLO Allogene Therapeutics | Reiterated: Buy | $10 | $1.06 | +843.40% | 20 | Mar 13, 2026 | |
| BNTX BioNTech SE | Reiterated: Buy | $155 | $87.51 | +77.12% | 19 | Mar 13, 2026 | |
| LEGN Legend Biotech | Reiterated: Buy | $70 | $24.29 | +188.18% | 10 | Mar 13, 2026 | |
| CRBU Caribou Biosciences | Reiterated: Buy | $7 | $0.4198 | +1,567.46% | 11 | Mar 9, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | n/a | $200.15 | - | 9 | Mar 9, 2026 | |
| CGEN Compugen | Reiterated: Buy | $4 | $2.14 | +86.92% | 20 | Mar 3, 2026 | |
| ZYME Zymeworks | Reiterated: Buy | $40 | $30.81 | +29.83% | 4 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $50.74 | - | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $18.95 | +58.31% | 22 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $8.17 | - | 28 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $17.84 | +96.19% | 19 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $51 | $71.74 | -28.91% | 30 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $8 | $1.32 | +506.06% | 25 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $10.61 | - | 17 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $127 → $145 | $169.32 | n/a | 12 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $259.67 | n/a | 1 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.47 | n/a | 4 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.7597 | n/a | 6 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 → $15 | $6.27 | n/a | 3 | Aug 23, 2022 |
Genmab
Oct 29, 2026
Reiterated: Buy
Price Target: $48 → $65
Current: $55.80
Upside: +16.49%
ArriVent BioPharma
Aug 13, 2026
Reiterated: Buy
Price Target: $32 → $45
Current: $14.16
Upside: +217.80%
Adicet Bio
Mar 16, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.99
Upside: -
Allogene Therapeutics
Mar 13, 2026
Reiterated: Buy
Price Target: $10
Current: $1.06
Upside: +843.40%
BioNTech SE
Mar 13, 2026
Reiterated: Buy
Price Target: $155
Current: $87.51
Upside: +77.12%
Legend Biotech
Mar 13, 2026
Reiterated: Buy
Price Target: $70
Current: $24.29
Upside: +188.18%
Caribou Biosciences
Mar 9, 2026
Reiterated: Buy
Price Target: $7
Current: $0.4198
Upside: +1,567.46%
Revolution Medicines
Mar 9, 2026
Reiterated: Buy
Price Target: n/a
Current: $200.15
Upside: -
Compugen
Mar 3, 2026
Reiterated: Buy
Price Target: $4
Current: $2.14
Upside: +86.92%
Zymeworks
Mar 3, 2026
Reiterated: Buy
Price Target: $40
Current: $30.81
Upside: +29.83%
Mar 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $50.74
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: $30
Current: $18.95
Upside: +58.31%
Feb 25, 2026
Reiterated: Hold
Price Target: n/a
Current: $8.17
Upside: -
Feb 24, 2026
Reiterated: Buy
Price Target: $35
Current: $17.84
Upside: +96.19%
Jan 14, 2026
Reiterated: Buy
Price Target: $51
Current: $71.74
Upside: -28.91%
Jan 13, 2026
Reiterated: Buy
Price Target: $10 → $8
Current: $1.32
Upside: +506.06%
Nov 11, 2025
Reiterated: Buy
Price Target: n/a
Current: $10.61
Upside: -
Nov 3, 2025
Reiterated: Buy
Price Target: $127 → $145
Current: $169.32
Upside: n/a
Apr 24, 2024
Reiterated: Hold
Price Target: n/a
Current: $259.67
Upside: n/a
Mar 21, 2024
Rated: Hold
Price Target: n/a
Current: $6.47
Upside: n/a
Jan 16, 2024
Rated: Hold
Price Target: n/a
Current: $0.7597
Upside: n/a
Aug 23, 2022
Reiterated: Buy
Price Target: $19 → $15
Current: $6.27
Upside: n/a